AbstrAct: Several studies suggest a role for kynurenic acid (KYNA) in the pathophysiology of schizophrenia. It has been proposed that increased brain KYNA levels in schizophrenia result from a pathological shift in the kynurenine pathway toward enhanced KYNA formation, away from the other branch of the pathway leading to quinolinic acid (QUIN). Here we investigate the levels of QUIN in cerebrospinal fluid (CSF) of patients with schizophrenia and healthy controls, and relate those to CSF levels of KYNA and other kynurenine metabolites from the same individuals. CSF QUIN levels from stable outpatients treated with olanzapine (n = 22) and those of controls (n = 26) were analyzed using liquid chromatographymass spectrometry. No difference in CSF QUIN levels between patients and controls was observed (20.6 ± 1.5 nM vs. 18.2 ± 1.1 nM, P = 0.36). CSF QUIN was positively correlated to CSF kynurenine and CSF KYNA in patients but not in controls. The CSF QUIN/KYNA ratio was lower in patients than in controls (P = 0.027). In summary, the present study offers support for an overactivated and imbalanced kynurenine pathway, favoring the production of KYNA over QUIN in patients with schizophrenia.
Introduction
Schizophrenia is one of our world's most devastating and complex psychiatric disorders. It is characterized by periods of delusional psychotic states and thought disturbance inter laced with a general state of anhedonia, avolition, and social withdrawal. Cognitive deficits are considered a core feature of the disorder. It follows that this lifelong disability often is accompanied by social and occupational exclusion.
In the past decade, the kynurenine pathway has been implicated in schizophrenia pathophysiology. 1, 2 Thus, eleva tion of brain kynurenic acid (KYNA), a neuroactive meta bolite of this pathway, is one of the most consistently found biochemical aberrations in schizophrenia and bipolar disorder with psychotic features. [3] [4] [5] [6] [7] [8] [9] [10] Apart from being an antagonist at the glycine site of the Nmethyldaspartate (NMDA) receptor, 11 KYNA also antagonizes the cholinergic α7 nicotinic receptor (α7nAChR). 12 Similar to synthetic NMDA receptor antagonists such as phencyclidine or ketamine, elevation of endogenous KYNA in rodents produces aberrant behavior thought to model certain aspects of schizophrenia. [13] [14] [15] [16] [17] [18] The kynurenine pathway accounts for approximately 95% of tryptophan metabolism and involves several neuroactive metabolites (Fig. 1 ). There are two main branches of the path way diverting from the common precursor lkynurenine. In a deadend branch, KYNA is produced from kynurenine via the astrocytic kynurenine aminotransferase (KAT) enzymes. In the other branch of the pathway, guarded by the enzyme kynurenine 3monooxygenase (KMO), 3hydroxykynurenine is produced from kynurenine and further metabolized to 3hydroxyanthranilic acid by kynureninase. This ultimately leads to the formation of the intermediate quinolinic acid (QUIN), which subsequently is transformed to nicotinamide adenine dinucleotide (NAD + ). QUIN is considered neurotoxic because of its agonistic action on the NMDA receptor and has mainly been studied with regard to neurodegeneration. 19 Thus, elevated levels of cerebrospinal fluid (CSF) QUIN have previously been reported in neurodegenerative disorders such as Huntington's disease 20 and Alzheimer's disease. 21 Recently though, QUIN was found to be elevated also in patients with severe depression and suicide attempters. 22, 23 The kynurenine pathway is critically regulated by inflammatory stimuli where the two ratelimiting enzymes tryptophan2,3dioxygenase (TDO) and indolamine2,3dioxygenase (IDO) are induced by proinflammatory cytokines. [24] [25] [26] The cellular source of QUIN in the brain is microglia, a cell type responsible for most inflammatory signaling in the brain.
Imbalanced Kynurenine Pathway in Schizophrenia
The literature on central levels of QUIN in schizophrenia is sparse. One early study found normal CSF QUIN levels in a small cohort of patients with schizophrenia. 27 Similarly, according to a postmortem study 3hydroxykynurenine, a pre cursor of QUIN, was unchanged in patients with schizophre nia, while kynurenine and KYNA were elevated. 4 No studies hitherto have investigated KYNA and QUIN in the same schizophrenia patient cohort.
The aim of the present study is to further characterize the kynurenine pathway in schizophrenia. We therefore analyzed CSF QUIN and related the levels to CSF KYNA, CSF kynurenine, and CSF tryptophan from the same patients with schizophrenia and from healthy controls.
Materials and Methods
Patients. Twentytwo Swedish Caucasian outpatients diagnosed with schizophrenia (n = 18; 11 males, 7 females) or schizoaffective disorder (n = 4; 2 males, 2 females), according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) 28 criteria, were included in the study. Dr Elisabeth Skogh and Dr Martin Samuelsson were the responsible psychiatrists for the DSMIV diagnosis. Full details of the study design and patient characteristics, includ ing serum and CSF concentrations of olanzapine, have been published elsewhere. 29 All of the patients were prescribed olan zapine as the only antipsychotic drug. The patients had been on medication with olanzapine for between 0.1 and 11 years (median 2 years) using the same dose (5-25 mg/day) for at least 14 days prior to CSF sampling. All patients were somatically healthy, as judged by routine laboratory analyses (electrolytes, hematology, kidney, liver, and thyroid function) and a physi cal examination. The Brief Psychiatric Rating Scale (BPRS) 30 and Global Assessment of Functioning (GAF) 28 index were used to evaluate symptoms and the level of function, respec tively. Mean (± SD) age of patients was 37.1 ± 7.6 years (range 23-50 years).
controls. As controls, 26 healthy Caucasian volunteers (18 males, and 8 females in the follicular phase of the men strual cycle) were recruited among medical students, hospital staff, and their relatives. All controls were somatically healthy, as judged by routine laboratory analyses (electrolytes, hema tology blood, kidney, liver, and thyroid function) and physical examination. Volunteers were subjected to a semistructured interview using the Structured Clinical Interview of DSMIV disorders (SCID Axis I) 31 and a questionnaire for personality disorders (SCID Axis II) 32 or interviewed by a psychiatrist to exclude mental illness. None of them had a family history of major psychosis or suicide in first or seconddegree rela tives, and they were all found to be free from current signs of psychiatric morbidity or difficulties in social adjustment at the time of sampling. Controls were not allowed to use any medication for at least one month prior to sampling; however, coffee and smoking were allowed. The mean (± SD) age of the controls was 24.9 ± 5.8 years (range 18-49 years).
CSF levels of kynurenine, KYNA, and tryptophan from a subsample of patients (n = 11, all males) and controls (n = 18, all males) have previously been published. 6 KYNA is a stable compound, neither degraded nor affected by storage time, nor by repeated thawing. 33 Since the sample size of the present study differs from our previously published paper, 6 levels of CSF kynurenine, KYNA, and tryptophan in the patients and controls included here are shown in Table 1 .
ethical consideration. The patients and controls were recruited at Linköping University Hospital. The study was approved by the Ethics Committee of Linköping University and the Swedish Medical Products Agency. The study was performed according to the Declaration of Helsinki for exper iments involving human subjects. All patients and healthy volunteers received written as well as verbal information and provided written consent prior to engaging in the study. Astra Zeneca did neither influence nor sponsor the clinical research performed at Linköping University. These data arise from a sample collection, not from a prospective trial, and this work is therefore not recorded in any clinical trial registry.
csF sampling. For lumbar puncture, a disposable needle (BD Whitacre Needle 0.7 × 90 mm) was inserted at the L 4-5 level with the subject in the right decubitus position. CSF was allowed to drip into a plastic test tube. The CSF samples were protected from light, centrifuged at 1438 g for 10 minutes (Sigma 203 centrifuge) within 30 minutes after the puncture, and divided into 2 to 3ml aliquots. Samples were stored at −70 °C pending analysis.
Analysis of olanzapine and laboratory variables. In order to analyze olanzapine in CSF and serum, a validated liquid chromatography/tandem mass spectrometry method was used as described in detail elsewhere. Calibration was performed using standards cover ing the range of the CSF concentration. Seven concentra tion points were used to establish a linear calibration curve and plotted using the ratio of analyte peak area over IS peak area after integration by Masslynx 4.1 software (Waters Corporation, Milford, MA, USA). Retention time for QUIN was 1.2 minutes.
The analysis of tryptophan, kynurenine, and KYNA was performed utilizing a reversedphase HPLC system as pre viously described. 5, 6 Fiftymicroliter samples were manually injected, and some samples were analyzed in duplicate, and the interindividual variation was less than 5%. statistical analysis. Plotting CSF QUIN residuals revealed one patient as an outlier in regard to CSF QUIN (standardized residuals . 3 SD). Data from this 29yearold male patient (CSF QUIN = 85.1 nM) were removed from all further analyses. For one patient the QUIN levels were below the lowest level of detection (LLOD), and the QUIN value for that patient was substituted for the LLOD value (5 nM). Background characteristics between patients and controls were compared using ttests or Chisquare tests. To study the effect of background characteristics on CSF QUIN concentra tion in the patient sample and in the controls sample we used correlation analyses or Mann-Whitney Utests. All correla tion analyses were performed using Spearman rank correlation tests. The comparisons of CSF kynurenine metabolites levels and the QUIN/KYNA ratio between patients and healthy vol unteers were performed using ttests. Logistic regression anal yses with age and sex as covariates were also performed. All reported Pvalues are two sided. All analyses were made using IBM SPSS Statistics 21.0 software (IBM SPSS Inc., Chicago, IL, USA). results background characteristics. The mean age (±SD) among the 21 patients was 37.5 (±7.5) years, and in the 26 controls 24.9 (±5.8) years (P , 0.0001). Sex, smoking status, height, weight, and body mass index (BMI) did not differ significantly between patients and healthy controls ( Table 2) .
Age was correlated to QUIN levels in controls (P = 0.012) but not in patients; there was however a trend toward correla tion also in patients (P = 0.113). Sex, height, weight, and BMI were not correlated to CSF QUIN in patients or in controls. In the patient group there was no correlation between CSF QUIN and psychiatric symptom ratings (BPRS and GAF); however, there was a tendency of positive correlation between CSF QUIN and serum levels of olanzapine (ρ = 0.414, P = 0.062). There was no correlation between CSF QUIN levels and CSF olanzapine levels (ρ = 0.333, P = 0.140). The mean CSF QUIN concentration did not differ between smokers/nonsmokers or male/females, in patients or in controls (Table 3) .
csF QUIN levels and the QUIN/KyNA ratio in patients and controls. The mean CSF QUIN concentration did not differ significantly between patients and controls (patients: 20.6 ± 1.51 nM vs. controls: 18.2 ± 1.08 nM; P = 0.198; Fig. 2 ). Adjusting the comparison for potential confounding by age and sex gave a similar result (Odds Ratio (OR) = 0.93, 95% confidence interval (CI) = 0.80-1.10; P = 0.355). The QUIN/ KYNA ratio was however close to significantly decreased in patients compared to healthy controls (P = 0.057). Adjusting the analysis for differences in age and gender distribution in two groups strengthened the association between the patient group and a decreased QUIN/KYNA ratio (OR = 0.66, 95% CI 0.45-0.95; P = 0.027).
relationship with other kynurenine metabolites. A correlation between CSF QUIN and CSF kynurenine lev els was detected in patients (ρ = 0.53, P = 0.014) but not in the controls (ρ = −0.32, P = 0.117). A similar pattern was seen regarding CSF QUIN and CSF KYNA in patients (ρ = 0.54, P = 0.016) and in controls (ρ = 0.12, P = 0.565). No significant correlation between CSF tryptophan and CSF QUIN levels was detected in patients (ρ = 0.32, P = 0.164), or in controls (ρ = −0.18, P = 0.373). See Table 1 for levels of kynurenine, KYNA, and tryptophan.
discussion
The present study offers support to the view of an imbal anced kynurenine pathway in patients with schizophrenia. Thus, levels of CSF kynurenine and CSF KYNA were found to be elevated whereas CSF QUIN levels were found to be in the same range in patients and in healthy controls. Fur thermore, a reduced QUIN/KYNA ratio was observed in patients, a result that is likely independent of smoking status. Moreover, QUIN was found to correlate to both kynurenine and KYNA in patients but not in controls. Despite a cor relation on the individual patient level, no difference in CSF QUIN levels between patients and controls was observed, suggesting that a putative enhancement of QUIN formation is substantially lower compared to the increase in kynurenine and KYNA in patients. The lack of correlation between CSF QUIN and CSF tryptophan might be attributed to the fact that no difference in the levels of neither tryptophan nor QUIN was observed. The present findings indicate an overactivated but also an imbalanced kynurenine pathway in patients with schizo phrenia, favoring the production of KYNA over QUIN.
The observed imbalance of the kynurenine pathway in schizophrenia is likely a result of a priority of lkynurenine metabolism toward the KYNA branch. Several mechanisms, acting independently or in combination, may induce such a disparity. The increased activity in the kynurenine pathway is likely attributed to an upregulation of the initial and rate lim iting enzyme TDO in patients with schizophrenia, tentatively induced by the increased secretion of the proinflammatory cytokine IL1β. 10, 26, 35, 36 Furthermore, the differential activa tion of the QUIN and KYNA branches of the kynurenine pathway is likely sought for in differences in activity of the enzymes guarding the entry of lkynurenine into the different branches of the pathway. Thus, compared to the higher capac ity of KAT enzymes, displaying K m values in the low millimo lar range, 37 the KMO enzyme gets saturated at relatively low concentrations (K m ≈ 20 µM), 38 and can therefore act as a rate limiting step in the synthesis of QUIN. In a situation where lkynurenine is elevated (eg, by induction of TDO) such a limitation of KMO might guard against excessive production of QUIN. A suboptimal function of KMO could also present an explanatory mechanism of the observed increase in KYNA but not in QUIN. 7, 8, 39 Such a scenario would thus shunt the metabolism of lkynurenine toward formation of KYNA, which indeed is observed in the present study. In agreement, experimental data show increased brain KYNA concentrations in Kmo knockout mice or following pharmacological blockade of KMO. [40] [41] [42] The importance of KMO in the kynurenine metabolism is supported by clinical data. A nonsynonymous single nucleotide polymorphism (SNP) in the KMO gene has been shown to affect the CSF KYNA levels in patients with schizophrenia 39 and bipolar disorder. 8 In addition, the activity 7 and expression 8 of the KMO enzyme was found to be reduced in prefrontal cortex in patients with schizophrenia and bipolar disorder patients with psychosis. Furthermore, a recent study suggests that the function of other enzymes in the pathway is worth investigating as well. Thus, examining rare mutations constituting a polygenic burden in schizophrenia, the lowest identified nominal Pvalue for disruptive mutations was for the enzyme kynureninase, converting 3hydroxykynurenine to 3hydroxyanthranilic acid. 43 Although these mutations did not reach statistical significance, it constitutes another piece of evidence for a downregulation of the QUIN branch of the kynurenine pathway in schizophrenia. The ratio between CSF levels of QUIN and KYNA is consequently telling us more than the individual measurements of QUIN and KYNA per se. Not only do these compounds represent different branches of the kynurenine pathway but also more importantly have opposing effects, with KYNA being an antagonist and QUIN an agonist of the NMDA receptor. A shift in the ratio between QUIN and KYNA is therefore likely to have an effect on behavioral domains.
The higher QUIN/KYNA ratio in controls is in line with the abovementioned studies and renders support to the hypothesis that KYNA is elevated in patients with schizophrenia likely because of a lower input of kynurenine into the QUIN branch of the pathway. In comparison, we recently showed that this ratio (QUIN/KYNA) was elevated in suicide attempters compared to healthy volunteers. 22 The kynurenine pathway is increasingly recognized as a pathophysiological promoter in several diseases. In this regard, the balance between the two oppositely acting metab olites, KYNA and QUIN, acting to antagonize and stimulate the NMDA receptor, respectively, is of major importance for glutamatergic neurotransmission. The present study, showing normal CSF QUIN levels concomitant with increased CSF kynurenine and CSF KYNA, resulting in a decreased QUIN/ KYNA ratio in patients, offers support to the view of an imbalanced kynurenine pathway in schizophrenia. These data are thus in line with previous findings showing elevated levels of KYNA and a compromised function of enzymes involved in the synthesis of QUIN in patients with schizophrenia.
